Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 306, Issue 4, 2014, Pages

  Kuster, Diederik W D ^a   Cardenas Ospina, Adriana ^b   Miller, Lawson ^b   Liebetrau, Christoph ^c   Troidl, Christian ^c   Nef, Holger M ^c   Möllmann, Helge ^c   Hamm, Christian W ^c   Pieper, Karen S ^d   Mahaffey, Kenneth W ^d   Kleiman, Neal S ^e   Stuyvers, Bruno D ^b   Marian, Ali J ^f   Sadayappan, Sakthivel ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c Kerckhoff Heart and Thorax Center   (Germany)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Acute coronary syndrome; Biomarker; Cardiac troponin I; cMyBP C; MYBPC3; Myocardial infarction

Indexed keywords

ACUTE CORONARY SYNDROME; BIOMARKER; CARDIAC TROPONIN I; CMYBP-C; MYBPC3; MYOCARDIAL INFARCTION;

ANIMALS; BIOLOGICAL MARKERS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; KINETICS; MYOCARDIAL INFARCTION; SWINE; TROPONIN I; TROPONIN T;

EID: 84894024486     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00846.2013     Document Type: Article

References (30)

1. Alcalai R, Planer D, Culhaoglu A, Osman A, Pollak A, Lotan C. Acute coronary syndrome vs. nonspecific troponin elevation: clinical predictors and survival analysis. Arch Intern Med 167: 276-281, 2007.
2. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE, 2nd Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Writing Group M, ACCF/AHA Task Force M. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123: e426-e579, 2011.
3. Apple FS, Christenson RH, Valdes R Jr, Andriak AJ, Berg A, Duh SH, Feng YJ, Jortani SA, Johnson NA, Koplen B, Mascotti K, Wu AH. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. Clin Chem 45: 199-205, 1999.
4. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 173: 1191-1202, 2005.
5. Barefield D, Sadayappan S. Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol 48: 866-875, 2010.
6. Chen SN, Ballantyne CM, Gotto AM Jr, Tan Y, Willerson JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma lowdensity lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 45: 1611-1619, 2005.
7. Decker RS, Nakamura S, Decker ML, Sausamuta M, Sinno S, Harris K, Klocke FJ, Kulikovskaya I, Winegrad S. The dynamic role of cardiac myosin binding protein-C during ischemia. J Mol Cell Cardiol 52: 1145-1154, 2012.
8. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H, Investigators ST. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292: 45-54, 2004.
9. Ferraro S, Ardoino I, Boracchi P, Santagostino M, Ciardi L, Antonini G, Braga F, Biganzoli E, Panteghini M, Bongo AS. Inside ST-elevation myocardial infarction by monitoring concentrations of cardiovascular risk biomarkers in blood. Clin Chim Acta 413: 888-893, 2012.
10. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127: e6-e245, 2013.
11. Govindan S, Kuster DW, Lin B, Kahn DJ, Jeske WP, Walenga JM, Leya F, Hoppensteadt D, Fareed J, Sadayappan S. Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction. Am J Cardiovasc Dis 3: 60-70, 2013.
12. Govindan S, McElligott A, Muthusamy S, Nair N, Barefield D, Martin JL, Gongora E, Greis KD, Luther PK, Winegrad S, Henderson KK, Sadayappan S. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J Mol Cell Cardiol 52: 154-164, 2012.
13. Govindan S, Sarkey J, Ji X, Sundaresan NR, Gupta MP, de Tombe PP, Sadayappan S. Pathogenic properties of the N-terminal region of cardiac myosin binding protein-C in vitro. J Muscle Res Cell Motil 33: 17-30, 2012.
14. Jaffe AS. Chasing troponin: how low can you go if you can see the rise? J Am Coll Cardiol 48: 1763-1764, 2006.
15. Jaffe AS, Apple FS. High-sensitivity cardiac troponin: hype, help, and reality. Clin Chem 56: 342-344, 2010.
16. Jurlander B, Clemmensen P, Wagner GS, Grande P. Very early diagnosis and risk stratification of patients admitted with suspected acute myocardial infarction by the combined evaluation of a single serum value of cardiac troponin-T, myoglobin, and creatine kinase MB(mass). Eur Heart J 21: 382-389, 2000.
17. Kontos MC, Roberts BD, Tatum JL, Roberts CS, Jesse RL, Ornato JP. Mortality based on the presenting electrocardiogram in patients with myocardial infarction in the troponin era. Am J Emerg Med 27: 146-152, 2009.
18. Kuster DW, Barefield D, Govindan S, Sadayappan S. A sensitive and specific quantitation method for determination of serum cardiac myosin binding protein-C by electrochemiluminescence immunoassay. J Vis Exp. In press.
19. Liebetrau C, Mollmann H, Nef H, Szardien S, Rixe J, Troidl C, Willmer M, Hoffmann J, Weber M, Rolf A, Hamm C. Release kinetics of cardiac biomarkers in patients undergoing transcoronary ablation of septal hypertrophy. Clin Chem 58: 1049-1054, 2012.
20. Lin B, Govindan S, Lee K, Zhao P, Han R, Runte KE, Craig R, Palmer BM, Sadayappan S. Cardiac myosin binding protein-C plays no regulatory role in skeletal muscle structure and function. PLoS One 8: e69671, 2013.
21. McCord J, Nowak RM, McCullough PA, Foreback C, Borzak S, Tokarski G, Tomlanovich MC, Jacobsen G, Weaver WD. Ninetyminute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 104: 1483-1488, 2001.
22. McMahon CG, Lamont JV, Curtin E, McConnell RI, Crockard M, Kurth MJ, Crean P, Fitzgerald SP. Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction. Am J Emerg Med 30: 267-274, 2012.
23. Morrow DA, de Lemos JA, Sabatine MS, Antman EM. The search for a biomarker of cardiac ischemia. Clin Chem 49: 537-539, 2003.
24. Razzaque MA, Gupta M, Osinska H, Gulick J, Blaxall BC, Robbins J. An endogenously produced fragment of cardiac myosin-binding protein C is pathogenic and can lead to heart failure. Circ Res 113: 553-561, 2013.
25. Sadayappan S. Cardiac myosin binding protein-C: a potential early-stage, cardiac-specific biomarker of ischemia-reperfusion injury. Biomark Med 6: 69-72, 2012.
26. Sadayappan S, Osinska H, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Seidman CE, Seidman JG, Robbins J. Cardiac myosin binding protein-C phosphorylation is cardioprotective. Proc Natl Acad Sci USA 103: 16918-16923, 2006.
27. Stork TV, Wu AH, Muller-Bardorff M, Gareis R, Muller R, Hombach V, Katus H, Mockel M. Diagnostic and prognostic role of myoglobin in patients with suspected acute coronary syndrome. North-Wurttemberg Infarction Study (NOWIS) Group. Am J Cardiol 86: 1371-1374, 2000.
28. SYNERGY Executive Committee. Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors. The SYNERGY trial: study design and rationale. Am Heart J 143: 952-960, 2002.
29. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Gabriel Steg P, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR. Third universal definition of myocardial infarction. Eur Heart J 33: 2551-2567, 2012.
30. Yusuf S, Pearson M, Sterry H, Parish S, Ramsdale D, Rossi P, Sleight P. The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction. Eur Heart J 5: 690-696, 1984.